Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry.

Mease, Philip J; Blachley, Taylor; Malatestinic, William N; Harrold, Leslie R; Dube, Blessing; Lisse, Jeffrey R; Bolce, Rebecca J; Hunter, Theresa M

Mease, Philip J; Blachley, Taylor; Malatestinic, William N; Harrold, Leslie R; Dube, Blessing; Lisse, Jeffrey R; Bolce, Rebecca J; Hunter, Theresa M.

Affiliation

Mease PJ; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.
Blachley T; CorEvitas, LLC, Waltham, MA, USA.
Malatestinic WN; Eli Lilly and Company, Indianapolis, IN, USA.
Harrold LR; CorEvitas, LLC, Waltham, MA, USA.
Dube B; University of Massachusetts Medical School, Worcester, MA, USA.
Lisse JR; CorEvitas, LLC, Waltham, MA, USA.
Bolce RJ; Eli Lilly and Company, Indianapolis, IN, USA.
Hunter TM; Eli Lilly and Company, Indianapolis, IN, USA.

Curr Med Res Opin ; 40(2): 315-323, 2024 02.

Article in En | MEDLINE | ID: mdl-38050693

Subject(s)

Antirheumatic Agents; Arthritis, Psoriatic; Biological Products; Spondylitis, Ankylosing; Humans; Female; Middle Aged; Male; Spondylitis, Ankylosing/drug therapy; Arthritis, Psoriatic/drug therapy; Antirheumatic Agents/therapeutic use; Registries; Biological Products/therapeutic use

Key words

DMARD; Rheumatic diseases; ankylosing spondylitis; biologics; effectiveness; patient-reported outcomes; real-world studies; registries

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spondylitis, Ankylosing / Biological Products / Arthritis, Psoriatic / Antirheumatic Agents Limits: Female / Humans / Male / Middle aged Language: En Journal: Curr Med Res Opin Year: 2024 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google